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Purpose: The aims of the study were to evaluate medication adherence and the influencing 
factors for isotretinoin and contraception (oral, patches, and rings) and to evaluate the concomi-
tant use of contraception and isotretinoin.
Methods: Reimbursed prescription data from January 2012 to August 2015 of all patients in 
Belgium were received from Pharmanet–National Institute for Health and Disability Insurance. 
Medication adherence was measured according to the medication possession ratio. The influence 
of gender and age was analyzed using the Mann–Whitney test and the Spearman coefficient 
correlation. The independence between adherence to contraception and adherence to isotretinoin 
was analyzed using the Pearson chi-square test of independence. Persistence was defined as 
the number of days between initiation and presumed end of treatment. The Kaplan–Meier 
method was used to plot the medication persistence curves, and the log-rank test was used to 
compare the curves. The concomitant use of contraception and isotretinoin was analyzed using 
descriptive statistics.
Results: The medication possession ratio was $0.8 for 46.1% of patients receiving isotretinoin and 
for 74.0% of women using contraception. For isotretinoin, this percentage decreased as the number 
of attempts increased (29.8% for the second attempt and 19.8% for more than two attempts). 
Men seemed more adherent than women, and a weak negative correlation between adherence and 
age was observed. The adherence data of isotretinoin and contraception were independent. The 
median persistence for isotretinoin treatment was 139 days (interquartile range 71–209) and was 
higher for men. Among women between 12 and 21 years old taking isotretinoin, 63.8% received 
at least one contraceptive prescription. However, 15.7% of women taking isotretinoin adhered 
to the use of contraception 1 month before, during, and 1 month after treatment.
Conclusion: Medication adherence to isotretinoin and contraception and compliance with 
the isotretinoin safety recommendation could be improved. Health service interventions, using 
pharmacy refill data, should be delivered to ensure patient safety and strict adherence to con-
traception when under isotretinoin treatment.
Keywords: medication possession ratio, persistence, patient safety, pregnancy prevention 
program
Introduction
Acne is described as a common chronic inflammatory dermatosis that significantly 
impacts patients’ quality of life, especially on an emotional, social and psychological 
level.1,2 The first-line treatment, according to the Up-to-Date guidelines, is a combination 
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of a topical retinoid, such as adapalene or tretinoin, and an 
oral antibiotic. Oral isotretinoin, a second-line treatment, is 
generally recommended for patients with severe acne or in 
the case of resistance to other treatments.3
Acne requires prolonged treatment, and medication 
adherence to anti-acne treatment is ∼50%.2 The consequences 
of low medication adherence to anti-acne treatment result in 
additional unnecessary treatments, frustration, patient dis-
satisfaction and increased medical expenses.4 Medication 
adherence is a longitudinal behavior defined as the process 
by which patients take their medications as prescribed.5 It can 
be measured by direct methods such as electronic monitoring, 
which registers the opening of the pillbox every day, or by 
indirect methods such as pharmacy refill data or self-report 
questionnaires that are easy to collect.6
Isotretinoin is a vitamin A derivative usually given 
over a 20-week course (16–24 weeks), with a dosage of 
0.5–1 mg/kg/day, depending on clinical response and side 
effects. The treatment seems to be more effective when a 
cumulative dose of 120 mg/kg is taken. Most of the time, 
a single attempt is sufficient to cure patients. If necessary, 
a second attempt can be considered at least 8 weeks after 
treatment discontinuation as the improvement of acne can 
continue until 8 weeks after discontinuation. Frequent 
side effects are mucous membrane and skin dryness, 
hepatotoxicity, lipid disorders, psychiatric disorders and 
teratogenicity.3,7,8 Because of the high teratogenic risk 
of the treatment, a pregnancy prevention program (PPP) 
for women of childbearing age was developed by Roche 
in 1988 and implemented in Europe for all oral isotretinoin 
generic drugs in 2003.9 One of the recommendations of 
this PPP is the use of an effective contraception method 
1 month before, during and 1 month after treatment.10 
Despite the implementation of this program, exposed 
pregnancies still occur in Europe and compliance with 
recommendations to prevent a birth defect risk seems to be 
limited.11 Beyond this, unintended pregnancies may occur if 
medication adherence to contraception is not sufficient.12,13 
However, medication adherence is not considered in the 
isotretinoin PPP and has never been assessed to a national 
level in Belgium.
The two aims of this study were, 1) to evaluate medica-
tion adherence and influencing factors of isotretinoin for men 
and women and for contraception (oral, patches and rings) 
for women, using the Belgian community pharmacy refill 
data, and 2) to evaluate the concomitant use of contracep-
tion 1 month before, during and 1 month after isotretinoin 
treatment for women in Belgium.
Methods
Data source
Community pharmacy refill data were extracted for all 
Belgian patients from Pharmanet. Pharmanet is a national 
health care claims database of the National Institute for 
Health and Disability Insurance (INAMI), which contains 
all administrative information on reimbursed medicines 
delivered to all patients in Belgium.14 Pharmanet coded 
data from January 2012 to August 2015 and sent to us two 
Excel files with the data of, 1) isotretinoin delivered to men 
and women, and 2) contraception delivered to women who 
received at least one prescription of isotretinoin.
study design and study population
This was a retrospective study using pharmacy refill data.
For evaluating medication adherence and influencing 
factors of isotretinoin and contraception, patients eligible 
for measuring medication adherence and persistence were 
those who received at least two prescriptions on two different 
days during the study period. More specifically for women’s 
contraception, we considered only oral contraceptives, 
patches and rings. Injections, implants, intrauterine devices 
and emergency contraception were excluded as we needed 
more than one prescription to apply the medication posses-
sion ratio (MPR) calculation.
For evaluating the concomitant use of contraception 
and isotretinoin, the inclusion criterion for evaluating the 
concomitant use of contraception and isotretinoin was 
women between 12 and 21 years old who received at least 
one prescription of isotretinoin. In Belgium, contraception 
methods are reimbursed for women aged #21 years but not 
systematically for older women. Therefore, data for women 
aged .21 years who did not receive a reimbursement were 
not accessible. To avoid underestimating compliance with this 
recommendation, we only considered women aged between 
12 and 21 years. To evaluate the concomitant use of contra-
ception and isotretinoin, all reimbursed contraception meth-
ods were considered for this analysis (oral contraceptives, 
patches, rings, injections, implants, intrauterine devices and 
emergency contraception).
Measurement
Medication adherence and medication persistence
To measure medication adherence, we used the MPR. 
For each patient, we divided the total days of medication 
supplied within the refill interval by the number of days 
in the refill interval (with this method).15 The total days 
of medication supplied were measured by multiplying the 
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number of packages delivered by the average daily dose 
(number of defined daily doses [DDDs] per package). The 
refill interval was defined as the interval of days between 
initiation (date of the first prescription delivered) and the 
date of the last prescription delivered. For isotretinoin, data 
were divided according to the different attempts. A new 
attempt was considered to be made if a patient had a gap 
of .3 months between the presumed end of treatment (con-
sidering the medication supplied in the last prescription) 
and the next prescription. The date of the next prescription 
was then considered as the initiation of a new attempt. 
The interval of 3 months was chosen because a minimum 
of 8 weeks of treatment discontinuation is recommended 
between two attempts of isotretinoin, to which we added 
1 month because a patient might have made a stockpile of 
medications. For contraception, we measured medication 
adherence regardless of the method used (oral contracep-
tives, rings or patches) as a patient could have changed to 
another contraception method. Medication adherences for 
oral contraceptives, rings and patches were also measured 
separately for information.
As dosage was not accessible to calculate the number 
of days of medication supplied and because dosage of 
isotretinoin varies according to the patient, and the dosage 
of contraception varies according to the method used (oral 
contraceptive, patch and ring dosage), we used the defined 
daily dose (DDD). The DDD is the assumed average main-
tenance dose per day for a drug used for its main indication 
in adults and is fixed by the WHO Collaborating Centre for 
Drug Statistics Methodology.16 For example, the isotretinoin 
DDD is fixed at 30 mg per day.17
Patients were considered as adherent if the MPR 
was $0.8, which is the most common cutoff level used in 
the literature across chronic diseases.6 However, this cutoff 
level may vary depending on treatments and pathologies, such 
as HIV. A higher cutoff could be determined for contracep-
tion as only one missed dose could lead to a higher risk of 
pregnancy, depending on the timing of the missed dose. To 
the best of our knowledge, there is no defined cutoff level 
for isotretinoin or contraceptives in the literature. In order to 
compare results between isotretinoin and contraception and to 
compare our results with the findings from the literature, we 
chose 0.8 as the cutoff for isotretinoin and contraception.
Medication persistence was defined as the time between 
the initiation (date of the first prescription) and the presumed 
end of treatment (date taking into account the medication sup-
plied in the last prescription). Patients who had a presumed 
end of treatment during or after the first 3 months and the 
last 3 months of the available database were removed from 
the persistence analysis as discontinuation was impossible 
to determine.
concomitant use of isotretinoin and contraception
To measure the concomitant use of isotretinoin and con-
traception for women, we merged the isotretinoin and the 
contraceptive databases, using a unique ID code for each 
patient. As the age of sexual consent is defined as 16 years 
in Belgium, we also separated results into two age groups in 
the analysis: 12–15 years and 16–21 years.
ethical approval
The protocol and the request to obtain insurance data were 
sent to Pharmanet-INAMI in December 2015, who submitted 
our demand to the Evaluation Committee for Drugs. This 
committee, which sits at INAMI, considers, in particular, 
the possible risks in respect of privacy. The approbation was 
received in February 2016. All received data were already 
processed and anonymized by Pharmanet. The use of anony-
mous data for retrospective research in Belgium does not 
require approval from an ethics committee.
statistical analysis
We used descriptive statistics – median and interquartile 
range (P25–P75) for continuous variables and percentages 
for categorical variables – to describe medication adherence 
and concomitant use of isotretinoin and contraception, using 
STATA IC13®. The influence of gender and age on adher-
ence was analyzed using the Mann–Whitney test and the 
Spearman coefficient correlation, respectively. The indepen-
dence between medication adherence for contraception and 
isotretinoin was analyzed using the Pearson chi-square test of 
independence. The Kaplan–Meier method was used to plot the 
medication persistence curves. This analysis provided a visu-
alization of medication persistence for isotretinoin treatment 
based on gender. The log-rank test was used to compare the 
medication persistence curves. We only considered medica-
tion adherence for isotretinoin in the first attempts to evaluate 
the influence of gender and age, to evaluate the independence 
between medication adherence for contraception and isot-
retinoin, and to plot the medication persistence curves.
Results
study population
We received a database of 86,754 patients to whom at least 
one prescription of isotretinoin had been delivered. The final 
study population for each part is described in Figure 1.
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Medication adherence and medication 
persistence
Men represented 52.5% of the isotretinoin database, and isot-
retinoin was mostly prescribed by dermatologists (79.4%). 
Contraception were mostly prescribed by general practi-
tioners (52.8%). For isotretinoin, 46.1% of patients had an 
MPR $0.8 in the first attempt, 29.8% in the second attempt 
and 19.8% for more than two attempts. The median (inter-
quartile range [IQR]) persistence was 139 days (71–209) in 
the first attempt, 40 days (20–104) in the second attempt and 
21 days (20–70) for more than two attempts. For contracep-
tion, an MPR $0.8 was observed for 74.0% of patients, and 
the median persistence was 826 days (491–1,185). When 
contraception data were separated based on the contraception 
method, an MPR $0.8 was observed for 73.4% of patients 
with oral contraceptives, 72.0% of patients with rings and 
77.4% of patients with patches (Table 1).
Isotretinoin – influence of gender
For the first attempt, men had a median MPR of 0.82 
(0.53–1.16) and 52.0% had an MPR $0.8. For women, 
the median MPR was 0.66 (0.42–1.03) and 39.4% had an 
MPR $0.8. According to the Mann–Whitney test, men were 
more adherent than women (p-value ,0.001).
isotretinoin and contraception – association with age
A weak but significant negative correlation between medi-
cation adherence and age was observed for isotretinoin 
(r
s
=−0.0461, p-value ,0.001) and contraception (r
s
=−0.1096, 
p-value ,0.001).
isotretinoin and contraception – test of 
independence
According to the Pearson chi-square test, medication adher-
ences for isotretinoin and contraception were independent 
(p-value =0.842).
Figure 1 Flow chart of the study population.
86,754 patients
464,174 prescriptions
1. Measurement of
medication adherence
to isotretinoin
44,481 ♂ + 42,273 ♀
403,761 prescriptions
2. Measurement of
medication adherence
to contraception for
women taking
isotretinoin
16,605 ♀
60,413 prescriptions
3. Concomitant use
of isotretinoin and
contraception
16,605 ♀
Exclusion of women
younger than 12 and
older than 21 years
Exclusion
of patients
with only one
prescription
Exclusion of 
– Injections, implants,
intrauterine devices
and emergency
contraception
– Patients with only
one prescription
67,657 patients
384,664 prescriptions
Oral contraceptives
12,563 patients
58,092 prescriptions
Contraception
12,610 patients
59,544 prescriptions
Patches
62 patients
253 prescriptions
Rings
250 patients
1,199 prescriptions
10,919 women taking
isotretinoin with at least one
prescription for contraception
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isotretinoin – medication persistence curves
As shown in Figure 2, medication persistence seems higher for 
men than for women. The log-rank test, which compares the 
curves based on gender, is statistically significant (p,0.001). 
The medication persistence median (95% CI) is higher 
for men, at 145 (144–147) days, than for women, at 131 
(129–133) days.
concomitant use of isotretinoin and 
contraception
In the database, 17,112 women who received isotretinoin 
were aged between 12 and 21 years (n=3,568 for women 
aged between 12 and 15 years and n=13,544 for women aged 
between 16 and 21 years) and 63.8% (n=10,919) received at 
least one prescription of a contraception method (44.7% for 
12–15 years and 68.8% for 16–21 years).
Among women who were prescribed at least one pre-
scription of a contraception method, 24.5% (n=2,679/10,919) 
followed the recommendation to have an effective con-
traception method 1 month before, during and 1 month 
after treatment (14.1% for 12–15 years and 26.3% for 
16–21 years). In other words, among the 17,112 women 
between 12 and 21 years old taking isotretinoin, 15.7% 
(2,679/17,112) followed the recommendation. More women 
used a contraception method during and 1 month after 
isotretinoin treatment (74.1% and 72.1%, respectively) 
Table 1 Prescription information, sociodemographic data, MPr and medication persistence of the study population
Prescription information, 
sociodemographic data, MPR 
and medication persistence
Isotretinoin Contraception
First attempt Second attempt .2 attempts
number of patients 56,364 8,738 3,696 12,610
Age
Median (iQr) (years) 20 (17–28) 21 (17–33) 24 (18–41) 19 (17–23)
Prescribers
gPs (%) 18.5 33.7 44.2 52.8
Dermatologists (%) 79.4 62.1 50.0 11.7
gynecologists (%) 0.3 0.6 0.8 32.5
Others (%) 1.8 3.6 5.0 3.0
MPr
Median (iQr) 0.74 (0.48–1.11) 0.54 (0.32–0.89) 0.38 (0.24–0.68) 1.0 (0.78–1.17)
MPr $0.8 (%) 46.1 29.8 19.8 74.0
Persistence
Median (iQr) (days) 139 (71–209) 40 (20–104) 21 (20–70) 826 (491–1,185)
Note: iQr (P25–P75).
Abbreviations: gP, general practioner; iQr, interquartile range; MPr, medication possession ratio.
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Figure 2 Medication persistence curves for isotretinoin treatment according to gender.
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than 1 month before treatment and at initiation (35.7% and 
46.5%, respectively). Results of the concomitant use before, 
at initiation, during and after treatment by age groups are 
presented in Figure 3.
Discussion
Medication adherence
isotretinoin
In our study, 46.1% of patients taking isotretinoin had an 
MPR $0.8 during the first attempt. This percentage decreased 
as the number of attempts increased (29.8% for the second 
attempt and 19.8% for more than two attempts). A retrospec-
tive cohort study by Tan et al18 (USA), using the same method, 
found that 57.3% of patients taking isotretinoin were adherent 
during the 90 days following the first prescription. They also 
showed that medication adherence was higher with isot-
retinoin than with other anti-acne treatments, such as topical 
treatments or antibiotics. In a cross-sectional study by Dreno 
et al,2 using questionnaires across America, Europe and Asia, 
it was found that 54% of patients were adherent to isotretinoin. 
Finally, in another study by Zaghloul et al19 (England), using 
questionnaires and counting, it was found that mean adherence 
was 64.7%±24% and that patients taking isotretinoin are more 
adherent when they are taking the treatment for the first time 
rather than for an additional attempt (87.5% vs 60.5% mean 
adherence), which we also showed in our results. The authors 
put forward the hypothesis that patients lost confidence in 
the treatment following the first attempt failure.19 Our result 
(46.1%) is lower than the literature findings but the study 
population, the method and the defined period for measur-
ing medication adherence were not the same. For example, 
the period used to measure medication adherence in this 
study depended on the patient, whereas in the studies by Tan 
et al and Zaghloul et al, medication adherence for 3 months 
following the first prescription was examined.
The median persistence for isotretinoin treatment is 
139 days (19.8 weeks), which corresponds to the usual treat-
ment duration for a dosage of 0.5–1 mg/kg/day (16–24 weeks).7 
The median persistence, like the MPR, decreased as the num-
ber of attempts increased (40 days for the second attempt and 
21 days for more than two attempts). Isotretinoin treatment 
seems to be more effective when taking a cumulative dose of 
120 mg/kg. To our knowledge, there is no information about 
persistence for isotretinoin treatment in the literature.
contraception
Tan et al18 showed that 49.0% of patients taking an oral con-
traceptive for an anti-acne effect had an MPR $0.8. With the 
same method (MPR) but with a higher cutoff level of 0.9, 
Kazerooni et al20 showed that 39.4% of women taking or 
not taking isotretinoin were adherent to oral contraceptives. 
Our study showed higher results for contraception (74.0%), 
but our results only considered women who received a reim-
bursement for their contraception method and who received 
at least one prescription of isotretinoin. It is possible that 
women could be more motivated to use a contraception 
method due to a high teratogenic risk, and if they received 
a reimbursement.
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Figure 3 results of concomitant use of isotretinoin and contraception by age group.
Notes: In this figure, we considered women who received at least 1 prescription for a contraceptive. The percentage was calculated in dividing the number of women taking 
isotretinoin and receiving at least 1 prescription for a contraceptive (1 month before, at initiation, during, or 1 month after treatment) by the number of women taking 
isotretinoin.
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However, 26.6%, 28.0% and 22.6% of the population 
were not adherent to oral contraceptives, rings and patches, 
respectively. For contraception, one missed dose can lead to 
pregnancy, depending on the stage of the menstrual cycle. 
Considering this, patient education is important not only to 
avoid a missed dose but also to teach patients how to react in 
the case of a missed dose, according to their menstrual cycle. 
Therapeutic education is even more important for women 
taking a teratogenic medication. Stuart et al,21 who studied 
discontinuation for oral contraceptives, rings and patches, 
showed that 47%, 49% and 58% of women, respectively, 
discontinued their treatment during the first year of treat-
ment. In our study, 50% of women stopped their contracep-
tion before 2.3 years (829 days), which is longer than for 
the results of Stuart et al. However, again, our results only 
considered women who received at least one prescription 
of isotretinoin. A review of strategies to improve medica-
tion adherence to contraception methods concluded that a 
combination of intensive counseling, multiple contacts and 
reminders is needed.12
Influencing factors
Many factors influence medication adherence for chronic 
treatment, such as young age, which is often associated with 
a lower medication adherence.2,4,13,18,20,21 Zaghloul et al19 
found a significant negative correlation between medication 
adherence for anti-acne treatment and age, with a Spearman 
coefficient of −0.30. Our results showed a significant nega-
tive correlation for isotretinoin and contraception. However, 
the correlation coefficient was weak, which means that age 
was poorly associated with medication adherence in our 
study. This weak correlation may be explained by the tight 
distribution of age in our population.
Concerning gender, the literature has shown mixed results. 
Tan et al18 showed that men seem to be more adherent, whereas 
Zaghloul et al19 found the opposite. In our study, men were 
more adherent to isotretinoin than women (52.0% vs 39.4%, 
respectively). One hypothesis is that men are heavier than 
women overall and therefore received higher doses of isot-
retinoin. As the MPR was calculated according to the DDD, a 
higher dose for men would result in a higher MPR. According 
to the test of independence, medication adherences for isot-
retinoin and contraception were not associated. Other factors 
can influence medication adherence to isotretinoin and con-
traception, such as side effects, lack of satisfaction or lack of 
knowledge and education,2,4,13 but these factors were not evalu-
ated in this study. Concerning persistence, the median persis-
tence was 2 weeks longer for men (Figure 2). A hypothesis is 
that severe nodular acne and acne fulminans occur mostly in 
men, which could lead to longer treatment.22
concomitant use of isotretinoin and 
contraception
Among women 12–21 years old taking isotretinoin, 44.7% 
of women between 12 and 15 years received at least one 
prescription of contraception compared to 68.8% of women 
from 16 to 21 years. For both age groups, a low proportion 
of these women followed the main safety recommendation 
linked to isotretinoin; 14.1% and 26.3%, respectively. The 
difference between groups could be explained by an inactive 
sexual life at a younger age, as the age of sexual consent is 
fixed at 16 years in Belgium. However, Figure 3 shows that 
the proportion of women using a contraception method dur-
ing and after isotretinoin treatment was higher for women 
between 12 and 15 years old, in contrast to the lower propor-
tion of these women using a contraception method 1 month 
before the treatment (19.7%).
An American study analyzed the compliance with 
this recommendation before and after the implementation 
in 2006 of a stricter PPP (IPledge), among 113,578 and 
77,072 women, respectively.23 This study showed that after 
2006, 32% of women between 13 and 45 years old used 
isotretinoin and contraception concomitantly. This proportion 
was lower for younger women (13–17 years), 27% compared 
to 34% for older women (18–45 years). A Dutch study found 
that 53.9% of women (15–45 years) use a contraception 
method at the initiation of isotretinoin.24
Our results are low, particularly 1 month before treatment 
and at initiation, suggesting that health care professionals prefer 
to initiate isotretinoin and contraception together instead of 
following the recommendation to postpone isotretinoin treat-
ment. The importance of initiating the use of contraception 
before isotretinoin treatment should be clarified in the PPP in 
order to increase the adoption of the recommendation. More-
over, different reasons can lead practitioners not to prescribe 
contraception methods, such as sexual inactivity, tubal ligation 
or hysterectomy. In Belgium, 8% of women aged between 15 
and 54 years use sterilization as a contraception method.25 The 
development of future interventions to ensure patient safety 
should take these results into account, and recommendations 
for women taking a teratogenic medicine should be flexible 
depending on the woman’s condition.
strengths and weaknesses
First, all reimbursed prescriptions pass through the same 
institute in Belgium (Pharmanet-INAMI). Therefore, patients 
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taking isotretinoin and women aged between 12 and 21 years 
taking a contraceptive at the same time are all represented 
in the analysis. However, we have a more restricted view of 
women aged .21 years because reimbursement of contra-
ception takes place only in some situations and depends on 
the woman’s health insurance. Because of this restriction, 
the second aim of this study was not fully met as it did not 
represent all women of childbearing age.
Second, considering the easy access to Belgian prescrip-
tion data, we used the MPR to measure medication adherence. 
MPR is a method that is non-invasive for patients and is a 
rapid and economic method of analyzing a large retrospective 
database. However, medication adherence is longitudinal 
and can vary over time.5 MPR cannot monitor medication 
ingestion and does not reflect all aspects of medication adher-
ence such as initiation, implementation and persistence.6 
To complete our analysis, we measured medication per-
sistence and visualized it using the Kaplan–Meier method. 
Moreover, data on dosage and changes in treatment were 
not available, which can under- or overestimate medication 
adherence.
Third, we used the DDD to calculate the number of days 
of medication supplied, which reflects the normal dosage for 
contraception and isotretinoin. The DDD for isotretinoin is 
30 mg per day but the pharmaceutical specialties available 
on the market only have doses of 10, 20 and 40 mg. Dos-
age of isotretinoin depends on the patient weight and varies 
according to the clinical response and the occurrence of side 
effects, which can lead to a higher dosage at the beginning of 
treatment and a lower dosage at the end.8 Because we cannot 
predict the dosage evolution over time, we decided to use the 
DDD to decrease the dosage variation effect.
Fourth, the medication adherence results for contracep-
tion may have been underestimated as only three methods 
were taken into account due to the chosen measurement 
method. This limitation means that the first aim of this study, 
to evaluate medication adherence for contraception, was not 
fully met.
Finally, it is well known that a large enough sample size 
always leads to statistically significant results despite small or 
even trivial size effects.26 However, our data represented the 
entire population who received a prescription of isotretinoin 
in Belgium, which is rare in the literature, and it allowed us 
to discuss our results in a more clinical sense.
Conclusion
Medication adherence and compliance with the PPP are 
important for treatment effectiveness and patient safety. 
Health care professionals should pay more attention to 
women of childbearing age taking a teratogenic medication, 
particularly 1 month before treatment and at initiation. Inter-
ventions should be developed to improve compliance with 
isotretinoin safety recommendations, particularly 1 month 
before and at initiation of the isotretinoin treatment, but these 
recommendations should remain flexible and depend on the 
woman’s sexual condition. Pharmacy refill data are easily 
usable for estimating medication use in community pharma-
cies. Tools integrated into pharmacy software based on these 
data could be developed and implemented in practice to help 
pharmacists to detect low-adherent patients, for example 
using the MPR calculation, and to check the concomitant use 
of a contraceptive method.
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